logo
Boost Mental Alertness and Heart Health in a Pinch With This Acupoint

Boost Mental Alertness and Heart Health in a Pinch With This Acupoint

Epoch Times17-05-2025

In urgent situations, such as when someone collapses, loses consciousness, or experiences sudden chest pain, most of us instinctively reach for the emergency call button. However, traditional Chinese medicine (TCM) practitioners in ancient China utilized a natural emergency relief point on the pinky finger: the Lesser Rushing (Shao Chong, HT9) acupoint.
Shao Chong has significant potential in cases of acute crises. TCM views it as a life-restoring switch during emergencies and a valuable tool for addressing emotional or physical turmoil.
A Legacy Rooted in Classical Medicine
Shao Chong first appeared in the 'Zhen Jiu Jia Yi Jing,' the oldest surviving manual on acupuncture and moxibustion (
a gentle heat therapy with dried mugwort)
, compiled nearly 2,000 years ago. Shao Chong is classified as a Jing-Well point, a group of points located at the tips of fingers and toes known for their rapid effects, especially their ability to expel pathogenic heat and restore consciousness.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

China Makes Childbirth Change Amid Falling Birth Rate
China Makes Childbirth Change Amid Falling Birth Rate

Miami Herald

time15 hours ago

  • Miami Herald

China Makes Childbirth Change Amid Falling Birth Rate

China is moving to expand access to pain relief during childbirth as part of efforts to encourage mothers to have more children. Newsweek reached out to the Chinese Foreign Ministry via email for comment outside of office hours. China has one of the world's lowest fertility rates, with an estimated 1.2 children per woman as of 2024. This marked a slight rise over 2023, but remains far below the replacement rate of 2.1. The government has rolled out an array of pro-natal policies, from child subsidies to extending insurance coverage to in vitro fertilization, but with little effect, raising concerns that the shrinking pool of young workers, coupled with the rising share of retirees, will drag on growth in the world's second-largest economy. By the end of this year, all tertiary hospitals-those with more than 500 beds-across China will be able to administer epidural anesthesia to pregnant women throughout the childbirth process, according to the country's health authorities, as reported by the state media outlet China Daily. All secondary hospitals, or those with more than 100 beds, will be capable of providing this service by 2027. These institutions will be expected to strengthen related infrastructure and protocols, including dedicated procedure rooms that meet a high standard of sterilization. Efforts were also updated to include pain relief procedures throughout labor, encompassing early and post-labor assessments, as well as the diagnosis and treatment of possible complications. Hospitals must continuously track hospital-acquired infections and improve information sharing between anesthesia and obstetrics departments to monitor patients' conditions better, the notice said. Anesthesia is administered to just 30 percent of mothers during labor in China, compared to around 67 percent in the United States, the health officials said. This hesitance is due to a shortage of anesthesiologists in some areas, unregulated costs of the procedure, and lingering misconceptions about possible side effects, according to experts cited by China Daily. Yun Zhou, assistant professor of sociology at the University of Michigan, told Reuters: "Much of China's population decline is rooted in entrenched structural reasons. "Without fundamental structural transformations-from enhancing the social safety net to eliminating gender discrimination – the trend of population decline cannot be reversed." New measures continue to be introduced at both the central and local government levels. For example, Hohhot, the capital of the Inner Mongolia Autonomous Region, announced in January a subsidy of 10,000 yuan ($1,393) to couples who have their first child. However, experts are skeptical that these and other government-driven efforts are enough to reverse a demographic decline. Commonly cited obstacles to parenthood in China include long working hours, the rising cost of urban living, and a lack of support for women in the workplace. Related Articles Video Shows Chinese 'Militia' Ship Near US Ally's Disputed TerritoryMap Shows China's Visa-Free 'Circle of Friends'Satellite Photo Shows US Aircraft Carrier in Pacific Rivalry With ChinaDonald Trump Says China 'Not Easy' As Trade Talks Kick Off 2025 NEWSWEEK DIGITAL LLC.

China Makes Childbirth Change Amid Falling Birth Rate
China Makes Childbirth Change Amid Falling Birth Rate

Newsweek

time17 hours ago

  • Newsweek

China Makes Childbirth Change Amid Falling Birth Rate

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. China is moving to expand access to pain relief during childbirth as part of efforts to encourage mothers to have more children. Newsweek reached out to the Chinese Foreign Ministry via email for comment outside of office hours. Why It Matters China has one of the world's lowest fertility rates, with an estimated 1.2 children per woman as of 2024. This marked a slight rise over 2023, but remains far below the replacement rate of 2.1. The government has rolled out an array of pro-natal policies, from child subsidies to extending insurance coverage to in vitro fertilization, but with little effect, raising concerns that the shrinking pool of young workers, coupled with the rising share of retirees, will drag on growth in the world's second-largest economy. A nurse takes care of a newborn baby at a hospital on May 11, 2025 in Lianyungang, Jiangsu Province of China. International Nurses Day falls on May 12 every year. A nurse takes care of a newborn baby at a hospital on May 11, 2025 in Lianyungang, Jiangsu Province of China. International Nurses Day falls on May 12 every year. Wang Chun/VCG via Associated Press What To Know By the end of this year, all tertiary hospitals—those with more than 500 beds—across China will be able to administer epidural anesthesia to pregnant women throughout the childbirth process, according to the country's health authorities, as reported by the state media outlet China Daily. All secondary hospitals, or those with more than 100 beds, will be capable of providing this service by 2027. These institutions will be expected to strengthen related infrastructure and protocols, including dedicated procedure rooms that meet a high standard of sterilization. Efforts were also updated to include pain relief procedures throughout labor, encompassing early and post-labor assessments, as well as the diagnosis and treatment of possible complications. Hospitals must continuously track hospital-acquired infections and improve information sharing between anesthesia and obstetrics departments to monitor patients' conditions better, the notice said. Anesthesia is administered to just 30 percent of mothers during labor in China, compared to around 67 percent in the United States, the health officials said. This hesitance is due to a shortage of anesthesiologists in some areas, unregulated costs of the procedure, and lingering misconceptions about possible side effects, according to experts cited by China Daily. What People Are Saying Yun Zhou, assistant professor of sociology at the University of Michigan, told Reuters: "Much of China's population decline is rooted in entrenched structural reasons. "Without fundamental structural transformations—from enhancing the social safety net to eliminating gender discrimination – the trend of population decline cannot be reversed." What Happens Next New measures continue to be introduced at both the central and local government levels. For example, Hohhot, the capital of the Inner Mongolia Autonomous Region, announced in January a subsidy of 10,000 yuan ($1,393) to couples who have their first child. However, experts are skeptical that these and other government-driven efforts are enough to reverse a demographic decline. Commonly cited obstacles to parenthood in China include long working hours, the rising cost of urban living, and a lack of support for women in the workplace.

Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor
Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor

Yahoo

time18 hours ago

  • Yahoo

Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor

PEACHTREE CORNERS, Ga., June 10, 2025--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that it had received a purchase order and first payment from Hangzhou Dongye Medical Technology Company Ltd (HDMT) for 35 LuViva systems. HDMT will order directly from Guided Therapeutics and the devices will be assembled and tested by Guided Therapeutics' Chinese partner, Shandong Yaohua Medical Instrument Corporation (SMI). HDMT is in Hangzhou City, Zhejiang Province, where it is the exclusive gynecology products provider for 42 hospitals that perform approximately two million cervical cancer screenings annually. Said Yang Dongye, CEO of HDMT: "We are extremely impressed with the performance of LuViva and our goal is to eventually replace the current screening tests with LuViva." The purchase order for $700,000 is to supply HDMT with 35 systems over the next eight months starting in July of this year. "We are extremely pleased to be working with HDMT to bring LuViva to Zhejiang Province and anticipate making initial shipments next month," added Mark Faupel, Guided Therapeutics' CEO. "Working directly with an exclusive provider of gynecology products that can potentially conduct two million LuViva tests each year is a major advance for GTI." About Guided Therapeutics Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company's first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc. Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics' actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading "Risk Factors" in Guided Therapeutics' reports filed with the SEC, including Guided Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and subsequent filings. View source version on Contacts Mark FaupelGuided Therapeutics770-242-8723

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store